Clinical trial · no report yet · Phase 3
OrigAMI-3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- NCT06750094 ↗
- Recruiting
- Janssen Research & Development, LLC
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 6 | |
| X threads | 6 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Colorectal Neoplasms
- Interventions
- Amivantamab; Cetuximab; Bevacizumab; 5-fluorouracil; Leucovorin calcium/Levoleucovorin; Irinotecan
- Arms
- Arm A: Amivantamab + FOLFIRI · Experimental
- Arm B: Cetuximab or Bevacizumab + FOLFIRI · Active comparator
- Enrollment
- 700 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Dec 12, 2024
- Primary completion
- Dec 15, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06750094 · updated Sep 25, 2026